Tailored Immunotherapy Approach With Nivolumab ± Ipilimumab for Advanced Transitional Cell Carcinoma After Platinum-Based Chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial
Lancet Oncol 2023 Feb 28;[EPub Ahead of Print], MO Grimm, CB Grün, G Niegisch, M Pichler, F Roghmann, B Schmitz-Dräger, G Baretton, M Schmitz, C Bolenz, S Foller, K Leucht, U Schumacher, M Schostak, J Meran, W Loidl, F ZengerlingFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.